Search

Your search keyword '"Müller-Richter U"' showing total 142 results
Start Over Author "Müller-Richter U"
142 results on '"Müller-Richter U"'

6. 155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT

Author

Klinghammer, K., primary, Saba, N.F., additional, Castelluci, E., additional, Colevas, A.D., additional, Rutkowski, T., additional, Greil, R., additional, Thurner, D., additional, Müller-Richter, U., additional, Di Giacomo, A.M., additional, Grewal, J., additional, Ottensmeier, C.H.H., additional, Atasoy, A., additional, Shpyro, S., additional, Brück, P., additional, Dias, J., additional, Ganser, C., additional, Türeci, Ö., additional, and Sahin, U., additional

Published
2022
Full Text
View/download PDF

7. 877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC

Author

Saba, N.F., Klinghammer, K., Castelluci, E., Colevas, A.D., Rutkowski, T., Thurner, D., Müller-Richter, U., Maio, M., Grewal, J.S., Ottensmeier, C.H.H., Dias, J., Yang, H., Das, R., Furlanetto, J., Herzfeldt, A-K., Kühnle, M-C., Ulges, A., Alles, J., Türeci, Ö., and Sahin, U.

Published
2024
Full Text
View/download PDF

12. LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Author

Argiris, A., primary, Harrington, K., additional, Tahara, M., additional, Ferris, R.L., additional, Gillison, M., additional, Fayette, J., additional, Daste, A., additional, Koralewski, P., additional, Mesia Nin, R., additional, Saba, N.F., additional, Mak, M., additional, Álvarez Avitia, M.A., additional, Guminski, A., additional, Müller-Richter, U., additional, Kiyota, N., additional, Roberts, M., additional, Khan, T.A., additional, Miller-Moslin, K., additional, Wei, L., additional, and Robert Haddad, R., additional

Published
2021
Full Text
View/download PDF

25. Hohe Prävalenz bisphosphonatassoziierter Kieferosteonekrosen bei rheumatischer Grunderkrankung – eine monozentrische Studie mit 198 Patienten

Author

Streit, A, Brands, RC, Krone, M, Hartmann, S, Müller-Richter, U, Kübler, AC, Gadeholt, O, Schmalzing, M, Tony, HP, and Schwaneck, EC

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Bisphosphonate (BP) werden zur Therapie der Osteoporose eingesetzt und gelten als nebenwirkungsarm. Die schwerwiegende Nebenwirkung der bisphosphonatassoziierten Osteonekrose des Kiefers (BONJ) wurde bislang vor allem bei Malignompatienten beobachtet, die BP intravenös bekamen. Bei [zum vollständigen Text gelangen Sie über die oben angegebene URL], 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2017
Full Text
View/download PDF

26. Die Bedeutung von MAGE-A9 als prognostisches Markerprotein und dessen Rolle bei der Strahlenresistenz von Kopf-Hals-Plattenepithelkarzinomen

Author

Meyer, T, Hartmann, S, Brisam, M, Kleinsasser, N, Polat, B, and Müller-Richter, U

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Einleitung: Das MAGE-A9 Protein gehört zur Familie der melanoma associated antigene-A (MAGE-A). Die Expression wird fast ausschließlich in Keimzellen oder malignen Tumoren, insbesondere Plattenepithelkarzinomen der Kopf-Hals-Region (HNSCC), nachgewiesen. In der vorgestellten Studie wurden[zum vollständigen Text gelangen Sie über die oben angegebene URL], 88. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie

Published
2017
Full Text
View/download PDF

29. Plattenepithelkarzinome des Kopf-Hals-Bereichs.

Author

Hartmann, S., Sayehli, C. M., Maurus, K., Bhola, N. E., Brands, R. C., Kübler, A. C., and Müller-Richter, U. D. A.

Abstract

Copyright of Der MKG-Chirurg is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018
Full Text
View/download PDF

49. Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines

Author

Reichert Torsten E, Kleinheinz Johannes, Reuther Tobias, Dowejko Albert, Müller-Richter Urs DA, and Driemel Oliver

Subjects
Specialties of internal medicine, RC581-951
Abstract

Abstract Background The immunological response to solid tumours is insufficient. Therefore, tumour specific antigens have been explored to facilitate the activation of the immune system. The cancer/testis antigen class of MAGE-A antigens is a possible target for vaccination. Their differential expression profiles also modulate the course of the cancer disease and its response to antineoplastic drugs. Methods The expression profiles of MAGE-A2, -A3, -A4, -A6 and -A10 in five own oral squamous cell carcinoma cell lines were characterised by rt-PCR, qrt-PCR and immunocytochemistry with a global MAGE-A antibody (57B) and compared with those of an adult keratinocyte cell line (NHEK). Results All tumour cell lines expressed MAGE-A antigens. The antigens were expressed in groups with different preferences. The predominant antigens expressed were MAGE-A2, -A3 and -A6. MAGE-A10 was not expressed in the cell lines tested. The MAGE-A gene products detected in the adult keratinocyte cell line NHEK were used as a reference. Conclusion MAGE-A antigens are expressed in oral squamous cell carcinomas. The expression profiles measured facilitate distinct examinations in forthcoming studies on responses to antineoplastic drugs or radiation therapy. MAGE-A antigens are still an interesting aim for immunotherapy.

Published
2009
Full Text
View/download PDF

50. Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma

Author

Kleinheinz Johannes, Berndt Alexander, Bauer Richard, Hakim Samer G, Müller-Richter Urs DA, Driemel Oliver, Reichert Torsten E, and Kosmehl Hartwig

Subjects
Specialties of internal medicine, RC581-951
Abstract

Abstract Background acantholytic squamous cell carcinomas (ASCC) and intraoral angiosarcoma share similar histopathological features. Aim of this study was to find marker for a clear distinction. Methods Four oral acantholytic squamous cell carcinomas and one intraoral angiosarcoma are used to compare the eruptive intraoral growth-pattern, age-peak, unfavourable prognosis and slit-like intratumorous spaces in common histological staining as identical clinical and histopathological features. Immunohistochemical staining for pancytokeratin, cytokeratin, collagen type IV, γ2-chain of laminin-5, endothelial differentiation marker CD31 and CD34, F VIII-associated antigen, Ki 67-antigen, β-catenin, E-cadherin, α-smooth-muscle-actin and Fli-1 were done. Results Cytokeratin-immunoreactive cells can be identified in both lesions. The large vascularization of ASCC complicates the interpretation of vascular differential markers being characteristic for angiosarcoma. Loss of cell-cell-adhesion, monitored by loss of E-cadherin and β-catenin membrane-staining, are indetified as reasons for massive expression of invasion-factor ln-5 in ASCC and considered responsible for unfavourable prognosis of ASCC. Expression of Fli-1 in angiosarcoma and cellular immunoreaction for ln-5 in ASCC are worked out as distinguishing features of both entities. Conclusion Fli-1 in angiosarcoma and ln-5 in ASCC are distinguishing features.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results